fidoptNaF PROSTATE PET-CT, CT to sodium fluoride PET
Low-dose CT (source) and 18F-sodium fluoride bone PET in body-weight SUV (target) of one prostate cancer patient's PET/CT session on a Philips Gemini TF, the CT brought onto the PET grid through their shared scanner frame (NaF PROSTATE collection).
9 test caseswhole bodysource CT, target PET
Read before comparing (10)
- Patients. Nine men with prostate cancer and known or suspected bone metastases, imaged on a Philips Gemini TF PET/CT between 2005 and 2007, 3 mCi of 18F-sodium fluoride prescribed (112 to 193 MBq in the headers). A case is the patient's first study date.
- Pairs. The attenuation-corrected whole-body PET ('[WB_CTAC] Total Body', 4 mm voxels) and the low-dose CT of its study and frame of reference (120 kV, 5 mm slices, 600 mm field), 117 to 143 minutes after the injection. NaF-PROSTATE-01-0001 has no whole-body pass: its PET is the last of three passes over the trunk, 57 minutes after the injection. On NaF-PROSTATE-01-0008 the 600 mm CT misses five slices and the complete 450 mm reconstruction of the same acquisition is used; 11% of its voxels over 0.3 SUV, the arms mostly, fall outside its field and the mask.
- Alignment. Nothing is registered: the CT is resampled onto the PET grid through the shared frame of reference with a cubic B-spline, air outside it, and rounded to whole Hounsfield units (the spline undershoots below -1024 HU at the body's edge).
- Target. Body-weight SUV from the PET's Bq/mL and its dose, weight and decay information (AutoPET_CTPET_Syn.suv_factor). The headers of NaF-PROSTATE-01-0001 to 0003 name fluorodeoxyglucose, a protocol default (the others sodium fluoride): the collection is NaF only, and the images show the skeleton's uptake, not FDG's.
- Uptake. NaF marks bone turnover: the skeleton, the metastases, degenerative joints and the bladder's urine are bright, soft tissue is near 0.5 SUV. A metastasis the CT barely shows counts against every method.
- Mask. The body where both images hold data, lungs included (AutoPET_CTPET_Syn.body), 67 to 100 litres.
- Range. A dynamic range of 20 SUV, as in the other CT to PET datasets; bone metastases and the bladder reach 28 to 114 SUV, past it.
- Baseline. On the nine test cases a constant at the target's median inside the mask scores an MAE of 0.6 (0.5 to 0.9) SUV, a PSNR of 21.5 (14.4 to 26.5) dB and an SSIM of 0.64 (0.59 to 0.68).
- Ranked apart. Nine patients give nine test cases, where a main leaderboard needs ten, and no development case.
- Overlap. No other descriptor names this collection or its patients.
No method has a result on every case of this dataset yet.
Case by case
Click a score to look at that result: the target image, and over it the method's synthetic image. Underlined scores have their image; for the others you see the case without the result.
About the data
- Test cases
- All nine patients are test cases, one study each, the first by date: the collection holds nine, so none is left for development. Their repeat baselines and follow-up studies are not used.
- Truth
- target image as released the attenuation-corrected 18F-NaF PET of the same PET/CT session in body-weight SUV, aligned by the scanner frame
- Source
- www.cancerimagingarchive.net/collection/naf-prostate
doi.org/10.7937/K9/TCIA.2015.ISOQTHKO
services.cancerimagingarchive.net/nbia-api/services/v1/getSeries?Collection=NaF%20PROSTATE - Licence
- CC BY 3.0